It enrolled 466 patients (median duration 11 yrs). Its 'clinical effectiveness' design meant all consenting eligible patients were entered whether or not they would take more DMARDs. Three-year hospital follow-up and community care by specialist nurses with annual hospital review resulted in similar deteriorations in HAQ scores. Community-based care was slightly more cost-effective [20] . There was heterogeneity between centres; social deprivation varied and was associated with worse function and greater improvements with treatment [21] .
A critique [22] of the British rheumatoid outcome study group (BROSG) trial noted that patients receiving community care changed DMARDs more frequently than expected and patients receiving hospital care were often unwilling to use DMARDs intensively, suggesting individual patients' responses are more important than the context in which care is provided. There is debate about the best assessments in late RA. Systematic reviews show HAQ [23] and disease activity assessments [24] are insensitive to DMARDs and biologics in late RA. HAQ scores mainly reflect joint damage in late RA [25, 26] . DAS28, which was developed to assess early RA [27, 28] may be less relevant in late RA than composite measures like 'overall status in rheumatoid arthritis' (OSRA) [29] . Interestingly, in the BROSG trial, OSRA suggested a significant benefit from intensive treatment [30] ( Table 1) .
One conclusion from these trials is that remission may be an unrealistic goal in late RA. Those patients receiving intensive DMARD therapy in the BROSG trial achieved mean swollen joint counts under 3 and mean ESRs under 25 mm/h at the end of 3 yrs' follow-up; these levels are comparable with long-term results with biologics [31] [32] [33] [34] [35] that also rarely achieve remission [36, 37] . Good symptom control may be a more realistic target in late RA.
Another conclusion is that patients with late RA stabilized on DMARDs, who have well-controlled symptoms, annual specialist review combined with urgent specialist access is sufficient when the need arises. Local factors like deprivation may modulate the need for specialist input. Although patients and clinicians recognize the importance of timely access to specialists [38] , it seems reasonable to aim for structured long-term primary-carebased supervision involving specialist rheumatology nurses together with annual specialist review. 
